Thromb Haemost 1984; 52(03): 364
DOI: 10.1055/s-0038-1661217
Letter to the Editor
Schattauer GmbH Stuttgart

Thromboxane Synthase Inhibition Combined with Thromboxane Receptor Blockade: A Step Forward in Antithrombotic Strategy?

Paolo Gresele
Department of Medical Research, Center for Thrombosis and Vascular Research, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
,
Elisabeth Van Houtte
Department of Medical Research, Center for Thrombosis and Vascular Research, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
,
Jef Arnout
Department of Medical Research, Center for Thrombosis and Vascular Research, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
,
Hans Deckmyn
Department of Medical Research, Center for Thrombosis and Vascular Research, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
,
Prof. Jos Vermylen
Department of Medical Research, Center for Thrombosis and Vascular Research, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 02 August 1984

Accepted 29 August 1984

Publication Date:
19 July 2018 (online)

 
  • References

  • 1 Vermylen J, Defreyn G, Carreras LO, Machin SJ, Van Schaeren J, Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet 1981; 1: 1073-1075
  • 2 Lewis P, Tyler HM. (eds) Dazoxiben. Clinical prospects for a thromboxane synthetase inhibitor Br J Clin Pharmacol 1983; 15: 1S-140S
  • 3 Gresele P, Deckmyn H, Huybrechts E, Vermylen J. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2 . Biochem Pharmacol 1984; 33: 2083-2088
  • 4 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2 . Thromb Res 1982; 26: 389-400
  • 5 Deckmyn H, Van Houtte E, Verstraete M, Vermylen J. Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom. Biochem Pharmacol 1983; 32: 2757-2762
  • 6 Bertelé V, Cerletti C, Schieppati A, Di Minno G, de Gaetano G. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet 1981; 1: 1057-1058
  • 7 Hornby EJ, Skidmore IF. Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production. Biochem Pharmacol 1982; 31: 1158-1160
  • 8 Rybicki JP, Le Breton G. Prostaglandin H2 directly lowers human platelet cAMP levels. Thromb Res 1983; 30: 407-414
  • 9 Gresele P, Deckmyn H, Arnout J, Lemmens J, Janssens W, Vermylen J. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 1984; 1: 991-994